HELX - Franklin Genomic Advancements ETF
This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements.
As of Jun 30, 2026: spot at $40.02, ATM IV 40.4%, max pain $30.00, net GEX $458.
- Sector
- Financial Services
- Industry
- Asset Management
- Market Cap
- $19.6M
- Beta
- 1.04
- 52-Week Range
- 26.991-39.71
- Dividend Yield
- $0.14
- IPO Date
- Feb 27, 2020
- Exchange
- CBOE
What HELX Looks Like to Options Traders Today
IV rank of 12.9% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($458) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.021) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The HELX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure.
Frequently asked HELX overview questions
- What is HELX?
- HELX is the ticker symbol for Franklin Genomic Advancements ETF, an listed exchange-traded fund. This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. Listed on CBOE. HELX is the ETF ticker shown on this page; ETF traders use the fund for diversified exposure to its underlying basket, for sector and factor rotation, and for hedging or replication strategies via the listed options chain.
- What does the HELX options snapshot look like today?
- As of Jun 30, 2026, the HELX options snapshot shows spot at $40.02, ATM IV 40.4%, IV rank 12.9%, max pain $30.00, net GEX $458, expected move 11.58%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are HELX's key statistics?
- Franklin Genomic Advancements ETF (HELX) carries a market capitalization of $19.6M, 52-week range of 26.991-39.71. Full holdings disclosure, expense ratio, and tracking-error history live on the per-ticker fundamentals page or the sponsor's site; daily NAV and premium/discount-to-NAV are accessible from the same view. These structural inputs frame how the ETF options market prices implied volatility relative to its constituents.
- What sector or industry does HELX belong to?
- Franklin Genomic Advancements ETF operates in the Financial Services sector, in the Asset Management industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare HELX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the HELX data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Fund-level fields (sponsor, expense ratio, holdings concentration where available) refresh from the vendor feed nightly. ETF-specific filings (N-CSR, N-PX, N-CEN) update on the SEC EDGAR cadence. FINRA microstructure data refreshes on the source's cadence; for ETFs the off-exchange volume signal is dominated by authorized-participant creation and redemption rather than directional flow.